Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
43%
Ph phase_2
2
29%
Ph not_applicable
2
29%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
N/ANon-phased studies
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Other(5)

Detailed Status

unknown5
Completed2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (42.9%)
Phase 22 (28.6%)
N/A2 (28.6%)

Trials by Status

unknown571%
completed229%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

NCT00992758
unknownphase_1

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

NCT00022906
unknownnot_applicable

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

NCT00022893
completedphase_2

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

NCT00022945
unknownphase_2

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

NCT00022932
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00992758Phase 1

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Completed
NCT00022906Phase 1

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Unknown
NCT00022893Not Applicable

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Unknown
NCT00022945Phase 2

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Completed
NCT00022932Phase 2

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Unknown
NCT00022958Not Applicable

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Unknown
NCT00022880Phase 1

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7